miR-371a-3p Predicting Viable Tumor in Patients Undergoing RPLND for Metastatic Testicular Cancer: The SWENOTECA-MIR Study.

Our study highlights miR-371a-3p as a fairly sensitive and highly specific marker for pre-chemotherapy seminomas, outperforming conventional markers. However, in pre-chemotherapy non-seminomas as well as in post-chemotherapy patients, we observed low sensitivity and no significant differences in miR-371a-3p levels before and after surgery, suggesting limited utility for miR-371a-3p in this context.